Recursion Pharmaceuticals Inc
RXRX
NASDAQ
Biotechnology
$3.16
USD
-0.15 (-4.53%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.78B
Volume 10.5M
Revenue
$54.85M
TTM
-15.1%
YoY
Gross Margin
3%
TTM
+199.3%
YoY
Net Income
$-518.88M
TTM
+20.1%
YoY
Operating Cash Flow
$-350.48M
TTM
+8.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 19.2 | 5.2 | 35.5 | 6.5 | 7.7 |
YoY Growth | +33.3% | -80.2% | +681.7% | -56.1% | -60.1% |
Cost of Revenue | 20.2 | 14.7 | 14.3 | 12.5 | 11.5 |
Gross Profit | -0.9 | -9.5 | 21.3 | -6.0 | -3.8 |
Selling, General & Administrative | 46.7 | 41.6 | 33.7 | 34.6 | 41.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 175.3 | 162.7 | 129.6 | 122.5 | 131.1 |
Operating Income | -176.2 | -172.2 | -108.3 | -128.5 | -135.0 |
EBITDA | -152.4 | -151.2 | -88.9 | -108.8 | -116.8 |
Other Income / Expense | 4.3 | 10.0 | 0.2 | 6.4 | 4.0 |
Total Other Income / Expense | 4.3 | 10.0 | 0.2 | 6.4 | 4.0 |
Income Before Income Taxes | -171.9 | -162.3 | -108.1 | -122.1 | -131.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | -4.6 | -0.0 |
Net Income | -171.9 | -162.3 | -108.1 | -117.5 | -131.0 |
Consolidated Net Income / Loss | -171.9 | -162.3 | -108.1 | -117.5 | -131.0 |
Net Income Attributable to Common Shareholders | -171.9 | -162.3 | -108.1 | -117.5 | -131.0 |
Basic EPS | -$0.41 | -$0.36 | -$0.21 | -$0.22 | -$0.25 |
Diluted EPS | -$0.41 | -$0.36 | -$0.21 | -$0.22 | -$0.25 |
Basic Shares Outstanding | 417.4M | 447.0M | 522.7M | 529.3M | 532.5M |
Diluted Shares Outstanding | 417.4M | 447.0M | 522.7M | 529.3M | 532.5M |